*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Hepatotoxicity induced by MK-677 BMJ case reports · human | PMID 40675653 |
| 2023 | Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration Drug testing and analysis · preclinical | PMID 36354265 |
| 2022 | LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report Experimental physiology · human | PMID 36303408 |
| 2022 | Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control Rapid communications in mass spectrometry : RCM · preclinical | PMID 35716382 |
| 2022 | A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial Hormone research in paediatrics · preclinical | PMID 35354138 |
| 2020 | Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males Translational andrology and urology · preclinical | PMID 32257855 |
| 2018 | The Safety and Efficacy of Growth Hormone Secretagogues Sexual medicine reviews · preclinical | PMID 28400207 |
| 2018 | Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats Yonsei medical journal · preclinical | PMID 30450851 |
| 2011 | MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study Archives of gerontology and geriatrics · human | PMID 21067829 |
| 2004 | The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture Journal of the American Geriatrics Society · human | PMID 15066065 |
| 1999 | Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · preclinical | PMID 10226793 |
| 1998 | MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism The Journal of clinical endocrinology and metabolism · human | PMID 9467534 |
| 1998 | The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo Journal of neuroendocrinology · preclinical | PMID 9535057 |
| 1997 | Growth hormone-releasing peptides European journal of endocrinology · preclinical | PMID 9186261 |
| 1997 | Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles The Journal of endocrinology · preclinical | PMID 9071975 |
MK-677 (Ibutamoren (MK-677)). Orally active non-peptide ghrelin-receptor agonist / GH secretagogue. Increases GH and IGF-1 with sustained (non-pulsatile) elevation; technically a small molecule, not a peptide, but grouped with GH secretagogues.
Commonly discussed uses: GH/IGF-1 elevation (research), appetite stimulation, investigational: muscle wasting, frailty. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Orally active non-peptide ghrelin-receptor agonist / GH secretagogue. Increases GH and IGF-1 with sustained (non-pulsatile) elevation; technically a small molecule, not a peptide, but grouped with GH secretagogues.
Reported considerations: increased appetite, water retention/oedema, lethargy, transient insulin resistance/raised fasting glucose, in one HF trial: increased adverse cardiac events. There is both human and animal/preclinical research, though the depth and quality vary by indication. Investigational small molecule; WADA-prohibited. Not approved for any indication. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 10mg/day, typical 12.5-25mg/day, high 25mg/day. Administration: oral. Half-life: ~24 hours.
Australian status: Not ARTG-registered; research; WADA prohibited (S2). Investigational small molecule; WADA-prohibited. Not approved for any indication. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: oral — no reconstitution; supplied as capsule/solution; storage: room temp / per product.
Commonly discussed combinations (anecdotal for unapproved compounds): MK-677 standalone or with GH-axis peptides (anecdotal). Stacking increases interaction/safety uncertainty.